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Background
• The CC Chemokine Receptor type 4
(CCR4) is highly expressed on
activated Th2 cells, regulatory T cells
(Treg), as well as cutaneous T-cell
lymphoma (CTCL) cells, making it a
prominent therapeutic target for
CTCL.

Results

Figure 6a. There
was no large
difference in
CCR4 scores or
CCR4+ cells
between treated
and untreated
groups.
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• Thus, inhibiting CCR4 may reduce
Treg accumulation and CTCL
development and progression.

Figure 2. Differences in tumor weight among the three
groups (G1: n=4, G2: n=4, G3: n=5) suggest a trend of
decreased tumor weight in treated mice.

Figure 1. Small molecule
CCR4 inhibitor C021,
dihydrochloride.

Figure 3. A lower average tumor weight in G2 (low dose,
n=7) compared to G1 (control, n=4) suggests treatment may
decrease tumor weight. One outlier (A2G24L: 0, 1840mg) was
removed.

Figure 4b. Ki67 IHC from
Arm 1, G1 (control)
group.

Figure 6b. CCR4 IHC from Arm 1, G1 (control) group.
Figure 6c. CCR4 IHC from Arm 1, G3 (high dose) group.

Summary
•

Hypothesis
The inhibition of CCR4 with C021
treatment may lead to decreased tumor
proliferation and decreased tumor
volume in CTCL.

•
Figure 4c. Ki67 IHC from
Arm 1, G2 (low dose)
group.

•

Methods

Conclusion

Study Group: We analyzed tissues from
mice injected with MJ CTCL cells, then
followed with treatment (Arm2) and mice
that were simultaneously injected with
treatment and tumor cells (Arm1).
Treatment: Mice were divided into 3
groups based on dosage of C021: G1
(control), G2 (low dose), G3 (high dose).

Figure 4d. Ki67 IHC from
Arm 1, G3 (high dose)
group.
Figure 4a. Arm 1 Ki67 average scores were compared by
group: G1 (control, n=4), G2 (low dose, n=3), G3 (high
dose, n=3). In Arm 1 samples, there was a slight decrease
in proliferation scores between G1 and G3.

Immunohistochemistry (IHC) assay:
A monoclonal rabbit antibody (D3B5) was
used to detect Ki67 at a 1:3000 dilution.
NBP1-86584 C-terminal polyclonal
antibody was used to detect CCR4 at a
1:500 dilution. Dako EnVision System kit
was used for staining.
Grading: The average of 3 graders was
taken for reading the expression of each
section.
• Ki67: Sections were graded based on
percentage of positive and negative
stained cells.
• CCR4: Sections were graded by
intensity (negative, weak, moderate,
strong) and percentage of cells within
each intensity class.

Tumor weight was lower in treatment
groups as compared to the control group,
especially in the Arm 1 high dose group.
We observed lower levels of Ki67
expression in C021 treatment groups.
CCR4+ cells were not drastically
decreased, but we observed large
necrotic areas in C021 treated tissues.

Our results suggest that C021, a small
CCR4 antagonist, has inhibitory effects on
CTCL cell proliferation, which may
contribute to decreased tumor volume in
xenograft CTCL mice.

Future Work
Figure 5b. Ki67 IHC
from Arm 2, G1 (control)
group.

• This study will benefit from larger
sample sizes in treatment groups,
which will decrease variance and lead
to more significant results.
• Tumor necrosis across treatment
groups could be analyzed to assess
anti-tumor effects.
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